# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Luke Sergott downgrades Medpace Hldgs (NASDAQ:MEDP) from Equal-Weight to Underweight and lowers the price t...
Jefferies analyst David Windley maintains Medpace Hldgs (NASDAQ:MEDP) with a Hold and raises the price target from $400 to $...
Rothschild & Co analyst Jamie Clark downgrades Medpace Hldgs (NASDAQ:MEDP) from Buy to Neutral and raises the price targ...
UBS analyst Dan Leonard downgrades Medpace Hldgs (NASDAQ:MEDP) from Neutral to Sell and raises the price target from $300 to...